The U.S. Food and Drug Administration (FDA) keeps track of drug recalls and safety alerts. Below is a list of drug recalls that could affect you.
Call Member Services at 1-888-276-2020 or talk to your doctor to find out more.
- September 21, 2020 – FDA Alerts of Perrigo's voluntary albuterol inhaler recall
- September 3, 2020 – RLC Labs, Inc., Issues Voluntary Nationwide Recall of All Lots of Nature-Throid® and WP Thyroid® with Current Expiry Due to Sub Potency
- August 5, 2020 – Ferring US Issues Voluntary Nationwide Recall of DDAVP® Nasal Spray 10 mcg/0.1mL, Desmopressin Acetate Nasal Spray 10 mcg/0.1mL, STIMATE® Nasal Spray 1.5 mg/mL Due to Superpotency
- July 8, 2020 – Lupin Pharmaceuticals, Inc. Issues Voluntarily Nationwide Recall of Metformin Hydrochloride Extended-Release Tablets, 500 mg and 1000 mg Due to the Detection of N-Nitrosodimethylamine (NDMA) Impurity
- July 6, 2020 – Granules Pharmaceuticals, Inc. Issues Voluntary Nationwide Recall of Metformin Hydrochloride Extended-Release Tablets USP, 750 mg Due to the Detection of N-Nitrosodimethylamine (NDMA) Impurity
- April 1, 2020 – FDA Requests Removal of All Ranitidine Products (Zantac) from the Market
- October 23, 2019 – Dr. Reddy’s Confirms its Voluntary Nationwide Recall of All Ranitidine Products in the U.S. Market
- December 20, 2018 – Terrific Care, LLC. / Medex Supply Dist, Inc. issues Nationwide Recall of CoaguChek Test Strips
- August 9, 2018 – Westminster Pharmaceuticals LLC Issues Voluntary Nationwide Recall of Levothyroxine and Liothyronine (Thyroid Tablets, USP) Due to Risk of Adulteration
Westminster Pharmaceuticals LLC is voluntarily recalling all lots, within expiry, of levothyroxine and liothyronine (thyroid tablets, USP) 15 mg, 30 mg, 60 mg, 90 mg, and 120 mg to the wholesale level. These products are being recalled as a precaution because they were manufactured using active pharmaceutical ingredients that were sourced prior to the FDA’s import alert of Sichuan Friendly Pharmaceutical Co., Ltd., which as a result of a 2017 inspection were found to have deficiencies with current good manufacturing practices (cGMP). Substandard cGMP practices could represent the possibility of risk being introduced into the manufacturing process. To date, Westminster Pharmaceuticals has not received any reports of adverse events related to this product.
- July 17, 2018 – Valsartan and Valsartan HCTZ
Prinston Pharmaceutical Inc., dba Solco Healthcare LLC., is voluntarily recalling all lots of Valsartan tablets, 40 mg, 80 mg, 160 mg, and 320 mg; and Valsartan-hydrochlorothiazide tablets, 80 mg/12.5 mg, 160 mg/12.5 mg, 160 mg/25 mg, 320 mg/12.5 mg, and 320 mg/25 mg to the consumer level. This product recall is due to the detection of a trace amount of an unexpected impurity, N-nitrosodimethylamine (NDMA), in an active pharmaceutical ingredient by the manufacturer — Zhejiang Huahai Pharmaceutical Co. Ltd. — in the manufacture of the subject product lots.
- March 2, 2018 – Zinbryta®
On March 2, Biogen® and Abbvie announced a voluntary withdrawal of Zinbryta (daclizumab), a multiple sclerosis (MS) drug, from the global market, noting concern about the drug’s evolving benefit/risk profile. As a result, FDA is working closely with the manufacturers to help ensure a well-organized withdrawal from the market in the United States, and to ensure that health care professionals have the information they need to carefully transition their patients using Zinbryta to another treatment.
- August 10, 2017 – Voluntary Nationwide Recall of All Liquid Products Manufactured by Pharmatech LLC and Distributed by Leader Brand, Major Pharmaceuticals, and Rugby Laboratories Due to Possible Product Contamination
The products subject to this recall were distributed nationwide to wholesale and retail facilities, including hospitals and pharmacies. As a precautionary measure based on additional information received from the FDA, the three distribution firms are recalling all lots within expiry of all liquid products manufactured by PharmaTech LLC.
- June 8, 2017 – OPANA ER
The U.S. Food and Drug Administration requested that Endo Pharmaceuticals remove its opioid pain medication, reformulated Opana ER (oxymorphone hydrochloride), from the market.